A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

Advances in the understanding of Alzheimer’s disease (AD) suggest that pathogenesis is not directly related to plaque burden, but rather to soluble toxic amyloid-beta oligomers (AßO). Therapeutic antibodies targeting Aß monomers and/or plaque have shown limited efficacy and dose-limiting adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbs, Ebrima, Silverman, Judith M., Zhao, Beibei, Peng, Xubiao, Wang, Jing, Wellington, Cheryl L., Mackenzie, Ian R., Plotkin, Steven S., Kaplan, Johanne M., Cashman, Neil R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614461/
https://www.ncbi.nlm.nih.gov/pubmed/31285517
http://dx.doi.org/10.1038/s41598-019-46306-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614461/
https://www.ncbi.nlm.nih.gov/pubmed/31285517
http://dx.doi.org/10.1038/s41598-019-46306-5

Ejemplares similares